Notwithstanding the available biomarkers of CEA, cancer antigen 19-9 (CA19-9) and cancer antigen 72-4 (CA72-4) are frequently used to monitor GC in the clinic (136). The gene discussed is CEACAM5; the disease is gastric cancer.